Madrigal Pharmaceuticals, Inc. - MDGL Total Company Value-to-Revenue Ratio

madrigalpharma.com (MDGL) - corporate logo

Madrigal Pharmaceuticals (MDGL) delegates drug manufacturing to external contractors, securing these partnerships through strict agreements. The EV/Sales trajectory reflects the market valuation of the business excluding debt, with 6028.64 determining the current value of this metric. Madrigal Pharmaceuticals (MDGL) implements bold scientific solutions for the therapy of severe liver pathologies. The monopoly launch of Rezdiffra following years of research will provide the firm with powerful operating leverage and access to a massive market.

MDGL Madrigal Pharmaceuticals: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Madrigal Pharmaceuticals Inc - analytical breakdowns and key metrics (MDGL)

Fundamental company valuation:madrigalpharma.com, MDGL
Manufactured product of Madrigal Pharmaceuticals, Inc.

For the biopharmaceutical business of Madrigal Pharmaceuticals (MDGL), the EV/Sales valuation serves as a tool for analyzing the enterprise value relative to generated revenue, excluding debt load. This metric correlates the total value of assets and liabilities with sales volume, allowing the influence of capital structure to be removed from the fundamental valuation. The trend in this EV/Sales valuation reveals abnormal price reactions to clinical trial results or changes in drug insurance coverage.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|CORT: EV/Sales Multiple|RYTM - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Akero Corp|Metsera Therapeutics (MTSR) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio moonlaketx.com (MLTX)|Company Value to Revenue Crinetics Pharmaceuticals CRNX|Enterprise Value-to-Revenue Ratio NewAmsterdam Pharma N.V. NAMS|Total Company Value-to-Revenue Ratio Soleno Therapeutics Inc (SLNO)|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)